VANCOUVER, BRITISH COLUMBIA--(Marketwired - Apr 20, 2016) - Cannabix Technologies Inc. (CSE:BLO)(OTC PINK:BLOZF) (the "Company") is pleased to announce that Professor Dr. (h.c.) Marilyn Huestis has been appointed as a Scientific Advisor to Cannabix Technologies Inc. Dr. Huestis is one of the world's foremost experts on the effects of marijuana use on driving impairment. Dr. Huestis will work with Cannabix in the development of its marijuana breathalyzer and provide key guidance on testing and regulatory approvals.
Dr. Huestis is a sought after international speaker, scholar and scientist. For the last 23 years, Dr. Huestis was a tenured Senior Investigator and Chief of Chemistry and Drug Metabolism at National Institute for Drug Abuse (NIDA's) Intramural Research Program (IRP) in Baltimore, Maryland and a Professor at the University of Maryland School of Medicine. Dr. Huestis is internationally known and respected for her work on cannabinoid agonists and antagonists, in utero drug exposure, and novel psychoactive compounds. She retired from NIDA in early 2016.
As a world-renowned expert on human drug testing, Dr. Huestis currently serves on the new National Commission on Forensic Science; the Organization of Scientific Area Committee on Toxicology; the World Anti-doping Agency's Prohibited List Committee; the Transportation Research Board Committee on Alcohol and Other Drugs; and the National Safety Council's Alcohol, Drugs and Impairment Division Executive Board.
Dr. Huestis received her Bachelor's degree (cum laude) in Biochemistry from Mount Holyoke College, a Master's in Clinical Chemistry with honors from the University of New Mexico, and a Ph.D. in Toxicology with honors from the University of Maryland School of Medicine. In 2010, she was selected for a Doctor Honoris causa in Medicine and Surgery from the Faculty of Medicine, University of Helsinki, Finland. Dr. Huestis has more than 410 peer-reviewed manuscripts in high impact journals in the field, serves on 6 editorial boards, and served as primary mentor to 13 toxicology doctoral students; and a member of the committee of 7 more from around the world.
Dr. Raj Attariwala, Cannabix's Chief Scientific Officer, states, "Cannabix is excited to be able to work with Dr. Huestis as her knowledge of the effects of marijuana use on driving impairment are second to none. Her work has been instrumental in the development of policy and understanding in this complex area of study. Her leadership at NIDA and vast network will be invaluable to Cannabix."
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the use of marijuana. In particular, Cannabix is focused on developing breath testing devices for THC detection that would target recent use of THC, in contrast to saliva or urine testing for THC which can be invasive and take considerable time for laboratory analysis. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
Rav Mlait, CEO
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.